| Literature DB >> 22991568 |
Eduardo Luzía França1, Iracema de Mattos Paranhos Calderon, Elisa Lima Vieira, Glilciane Morceli, Adenilda Cristina Honorio-França.
Abstract
This study was carried out with hyperglycemic pregnant women to investigate the transfer of antibody classes to newborns across the placenta or by colostrum and the functional activity of phagocytes in maternal blood, cord blood, and colostrum from diabetes mothers. Samples from maternal blood, cord blood, and colostrum were collected from 20 normoglycemic and 20 hyperglycemic pregnant women. We determined antibodies levels, superoxide release, phagocytosis and bactericidal activity of phagocytes. We demonstrated that IgG levels in cord blood were higher in the hyperglycemic group. IgA and IgM levels were higher in maternal than in cord blood samples. Plasma antibody levels were lower in hyper- than in normoglycemic women. The colostrum of diabetic mothers had lower IgA and IgG levels. Colostrum and maternal blood phagocytes when exposed to EPEC increased the superoxide release. Cord blood phagocytes of hyperglycemic group, independently of bacteria, had higher superoxide release. Colostrum and blood phagocytes from diabetic group exhibited some phagocytic and microbicidal activity in response to EPEC. Mononuclear phagocytes from cord blood had the lowest phagocytosis, and bactericidal activity for EPEC, regardless of glycemic status. These data showed that hyperglycemia altered IgG transfer across the placenta and decreases immunoglobulin levels in maternal blood and colostrum.Entities:
Mesh:
Substances:
Year: 2012 PMID: 22991568 PMCID: PMC3444004 DOI: 10.1155/2012/928187
Source DB: PubMed Journal: Clin Dev Immunol ISSN: 1740-2522
Mean (±SD) glucose level, leukocyte count, and viability in colostrum, maternal blood, and cord blood from normoglycemic and hyperglycemic women.
| Parameter | Sample | Normoglycemic | Hyperglycemic | Statistical contrast |
|---|---|---|---|---|
| Glucose level (mg/dL) | Colostrum | 76 ± 18.0 | 148.1 ± 31.8† | Colostrum versus blood |
| Maternal blood | 80.95 ± 9.24 | 111.3 ± 12.7† | Normo- versus hyperglycemic | |
| Cord blood | 75.3 ± 10.5 | 95.7 ± 5.7† | ||
|
| ||||
| Mononuclear phagocytes count (×106 cell/mL) | Colostrum | 4.7 ± 0.4 | 4.5 ± 0.7 | Colostrum versus blood |
| Maternal blood | 5.3 ± 0.7 | 5.1 ± 0.5 | Normo- versus hyperglycemic | |
| Cord blood | 3.5 ± 0.9* | 3.2 ± 1.1* | ||
|
| ||||
| Mononuclear phagocytes viability (%) | Colostrum | 94 ± 4.5 | 93 ± 4.2 | Colostrum versus blood |
| Maternal blood | 95 ± 5.4 | 93 ± 4.3 | Normo- versus hyperglycemic | |
| Cord blood | 95 ± 3.4 | 90 ± 5.7 | ||
*Statistical differences between leukocyte count in cord blood and leukocyte count in maternal blood and colostrum (within a column). †Statistical differences in glucose levels between normoglycemic and hyperglycemic women (in a row).
Mean (±SD) immunoglobulin level in colostrum, maternal blood, and cord blood from normoglycemic and hyperglycemic women.
| Parameter | Sample | Normoglycemic | Hyperglycemic | Statistical contrast |
|---|---|---|---|---|
| IgG (mg/dL) | Colostrum | 120.8 ± 43.7 | 82.5 ± 27.7† | Colostrum versus blood |
| Maternal blood | 2014.6 ± 261.6* | 1649.3 ± 207.8∗† | Normo- versus hyperglycemic | |
| Cord blood | 1940.4 ± 327.4* | 2570.9 ± 466.1∗#† | ||
|
| ||||
| IgA (mg/dL) | Colostrum | 417.8 ± 51.3 | 291.5 ± 90.3† | Colostrum versus blood |
| Maternal blood | 55.4 ± 7.1* | 43.0 ± 5.1* | Normo- versus hyperglycemic | |
| Cord blood | 24.4 ± 4.7∗# | 22.5 ± 8.8∗# | ||
|
| ||||
| IgM (mg/dL) | Colostrum | 36.2 ± 10.5 | 36.2 ± 8.5 | Colostrum versus blood |
| Maternal blood | 52.8 ± 13.8 | 37.3 ± 6.9† | Normo- versus hyperglycemic | |
| Cord blood | 13.5 ± 5.3∗# | 13.0 ± 7.7∗# | ||
Within a same group (normo- or hyperglycemic), *indicates statistical differences between colostrum and blood and #indicates differences between maternal blood and cord blood immunoglobulin levels. †Indicates statistical differences in immunoglobulin levels between normo- and hyperglycemic women (in a row).
Superoxide release by colostrum and blood mononuclear phagocytes (mean ± SD, N = 10 in each treatment).
| Phagocytes | Bacteria | Superoxide release (nmol) | ||
|---|---|---|---|---|
| Normoglycemic | Hyperglycemic | Statistical contrast | ||
| Colostrum | No | 1.9 ± 0.4 | 1.6 ± 0.1 | Phagocytes with bacteria versus without |
| Yes | 2.1 ± 0.5 | 1.5 ± 0.2 | ||
|
| ||||
| Maternal blood | No | 3.5 ± 1.1# | 4.9 ± 0.9# | Colostrum versus blood |
| Yes | 4.4 ± 0.2∗# | 6.1 ± 0.7+# | ||
|
| ||||
| Cord blood | No | 0.6 ± 0.2# | 3.8 ± 1.1+# | Normo- versus hyperglycemic |
| Yes | 1.2 ± 0.5* | 3.9 ± 0.9+# | ||
Colostrum and blood mononuclear cells were preincubated or not with EPEC. *Indicates differences between phagocytes incubated with bacteria and the control (without bacteria) within each group and sample; +indicates intergroup differences within each treatment (with or not bacteria) and sample; #indicates differences between sample (colostrum and blood) within each treatment (with or not bacteria) and group.
Figure 1Mean (±SD) phagocytosis index of colostrum, maternal, and cord blood MN cells (N = 10) determined using the acridine orange method. *Indicates statistical difference (P < 0.05) within normo- and hyperglycemic groups.
Figure 2Mean (±SD) bactericidal index of colostrum, maternal, and cord blood MN cells (N = 10) determined using the acridine orange method. *Indicates statistical difference (P < 0.05) within normo- and hyperglycemic groups.